Results 351 to 360 of about 355,585 (385)
Some of the next articles are maybe not open access.
Current Opinion in Hematology, 2006
Abstract Traditional anticoagulant drugs, including unfractionated heparin and warfarin, have several limitations. New anticoagulants have been developed that target a single coagulation factor and have predictable dose-response relationships. These include direct thrombin inhibitors and factor Xa inhibitors.
AGNELLI, Giancarlo, BECATTINI, Cecilia
openaire +6 more sources
Abstract Traditional anticoagulant drugs, including unfractionated heparin and warfarin, have several limitations. New anticoagulants have been developed that target a single coagulation factor and have predictable dose-response relationships. These include direct thrombin inhibitors and factor Xa inhibitors.
AGNELLI, Giancarlo, BECATTINI, Cecilia
openaire +6 more sources
Clinical Obstetrics and Gynecology, 1998
Outpatient management of women requiring treatment and prophylaxis against thromboembolic conditions during pregnancy and the postpartum period requires a coordinated effort between the patient, her obstetrician and, in certain cases, a hematologic consultant.
H L, Brown, R A, Bobrowski
openaire +2 more sources
Outpatient management of women requiring treatment and prophylaxis against thromboembolic conditions during pregnancy and the postpartum period requires a coordinated effort between the patient, her obstetrician and, in certain cases, a hematologic consultant.
H L, Brown, R A, Bobrowski
openaire +2 more sources
Anticoagulation clinics and the monitoring of anticoagulant therapy
International Journal of Cardiology, 1988Patients attending an anticoagulation clinic were studied to delineate predisposing risk factors for bleeding and thromboembolic episodes. Seventy-three patients were observed for a total of 921.8 patient-treatment months. The mean duration of treatment was 12.6 months (range 3-36 months).
R, Charney +3 more
openaire +2 more sources
Blood Reviews, 1991
Acquired antibodies to phospholipids form a heterogeneous group, which may be detected in vitro by the inhibition of phospholipid dependent tests of coagulation (lupus anticoagulant) and also by immunological assays, such that a combined approach is required for their reliable detection.
M D, Creagh, M, Greaves
openaire +2 more sources
Acquired antibodies to phospholipids form a heterogeneous group, which may be detected in vitro by the inhibition of phospholipid dependent tests of coagulation (lupus anticoagulant) and also by immunological assays, such that a combined approach is required for their reliable detection.
M D, Creagh, M, Greaves
openaire +2 more sources
Novel anticoagulants and the future of anticoagulation
Thrombosis Research, 2009Since its discovery during the first half of the 20th century by biochemists at the University of Wisconsin, warfarin (along with other vitamin K antagonists) has remained the only oral anticoagulant available to patients at risk for thromboembolism. After nearly 6 decades in clinical practice, we have learned much about warfarin. Although it is highly
openaire +2 more sources
Pharmacology of Anticoagulants
Disease-a-Month, 2012Antithrombotic drugs are used for the prevention and treatment of thrombosis. Targeting the various components of thrombosis, these agents include (1) antiplatelet agents; (2) anticoagulants; and (3) fibrinolytic agents. This review focuses on anticoagulants.
Loke, Chandravathi, MD +2 more
openaire +2 more sources
Arthritis & Rheumatism, 1976
AbstractThe clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anticoagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator complex of factors Xa, V, and phospholipid.
M, Boxer, L, Ellman, A, Carvalho
openaire +2 more sources
AbstractThe clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anticoagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator complex of factors Xa, V, and phospholipid.
M, Boxer, L, Ellman, A, Carvalho
openaire +2 more sources
Cardiology Clinics, 2012
Pregnancy-associated thrombosis is an important cause of morbidity and mortality during pregnancy. Anticoagulation therapy is an important component of the management of thrombotic complications in pregnancy but may result in fetal and maternal complications.
Sorel, Goland, Uri, Elkayam
openaire +2 more sources
Pregnancy-associated thrombosis is an important cause of morbidity and mortality during pregnancy. Anticoagulation therapy is an important component of the management of thrombotic complications in pregnancy but may result in fetal and maternal complications.
Sorel, Goland, Uri, Elkayam
openaire +2 more sources
Periprocedural Anticoagulation
Annals of Internal Medicine, 2023Management of patients taking anticoagulants around the time of a procedure is a common and complex clinical scenario. Providing evidence-based care requires estimation of risk for thrombosis and bleeding, knowledge of commonly used medications, multidisciplinary communication and collaboration, and patient engagement and education.
Anna L. Parks, Margaret C. Fang
openaire +2 more sources
Anticoagulation in the elderly
Current Opinion in Pulmonary Medicine, 2001Oral anticoagulation therapy has demonstrated benefit in the treatment and prevention of a variety of thromboembolic disorders. Most individuals who receive oral anticoagulant therapy are elderly patients with nonvalvular atrial fibrillation and acute or recurrent venous thromboembolism.
M C, Henderson, R H, White
openaire +2 more sources